<DOC>
	<DOCNO>NCT01093300</DOCNO>
	<brief_summary>In-stent restenosis ( ISR ) lesion consider one tough lesion interventional cardiologist encounter drug elute stent ( DES ) era . The current consensus treat ISR implantation another DES restenosed segment . However recent result paclitaxel-releasing balloon catheter ( PRBC ) ISR lesion encourage . The aim HOST-ISR trial investigate efficacy safety PRBC compare everolimus-eluting stent ( EES ) prevent neointimal growth ISR lesion . HOST-ISR trial multicenter , open-label , prospective , randomized trial test whether PRBC non-inferior EES prevent neointimal growth ISR lesion . It plan enroll total 264 patient ISR , randomize cohort 1:1 either PRBC EES . The primary endpoint in-segment late luminal loss 9 month angiographical follow-up .</brief_summary>
	<brief_title>Comparison Efficacy Paclitaxel-releasing Balloon Catheter System Versus Everolimus-Eluting Stent System Treatment In-Stent Restenosis Lesions - Harmonizing Optimal Strategy Treatment In-Stent Restenosis Lesions ( The HOST-ISR Trial ) -</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age least 18y Significant ISR lesion ( &gt; 50 % visual estimate ) previously stented de novo coronary artery Evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) ISR diameter stenosis &gt; 70 % Written , inform consent Target lesion ( ) locate native coronary artery within previously stented lesion previous stent diameter ≥ 2.5 mm ≤ 4.00 mm Target lesion ( ) amenable percutaneous coronary intervention Hypersensitivity aspirin , clopidogrel , heparin , sirolimus , paclitaxel radiocontrast medium Systemic sirolimus use within 12 month Female childbearing potential History bleeding diathesis know coagulopathy ( include heparininduced thrombocytopenia ) Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance Patients actively participate another drug device investigational study , complete primary endpoint followup period ISR leave main coronary artery Restenosis two stented bifurcation lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>